Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Clinical Effectiveness of Olaparib Monotherapy in Germline BRCA-Mutated, HER2-Negative Metastatic Breast Cancer in a Real-World Setting: Phase IIIb LUCY Interim AnalysisEur. J. Cancer 2021 Jun 01;152(xx)68-77, KA Gelmon, PA Fasching, FJ Couch, J Balmaña, S Delaloge, I Labidi-Galy, J Bennett, S McCutcheon, G Walker, J O'Shaughnessy
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.